What impacted Moleculin Biotech's selling expenses in 2024?

Moleculin Biotech's selling expenses in 2024 were not impacted by any specific factor as the data for these expenses is not available. However, the company's financial performance was influenced by several significant events:

1. **Quarterly Financial Performance**: The company reported a quarterly adjusted loss of 37 cents per share for the quarter ended December 31, 2024, which is higher than the same quarter last year's EPS of -$5.02. This indicates a deteriorating financial trend.
2. **Revenue Expectations**: Analysts expected the company to report a loss of $1.28 per share for the quarter, with reported revenue being zero, which matches the company's actual reported revenue. This suggests that the company's revenue projections were not met.
3. **Stock Performance**: Moleculin Biotech's shares had fallen by 35.9% this quarter, which could reflect investor sentiment and market perception of the company's prospects.
4. **Analyst Ratings and Price Target**: The average analyst rating on the shares is "buy," with a current price target set at $18.00. This suggests that while the stock has potential, analysts are cautious due to the company's current financial performance.
5. **Recent News**: The company's shares traded higher after announcing the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model, indicating investor interest in the company's research developments.

In conclusion, while specific selling expenses are not available, the company's financial performance in 2024 was impacted by negative earnings, revenue not meeting expectations, and stock price decline, with some positive sentiment from research developments.